LONGEVA.

CagriSema: adverse events and evidence limits

In the 68-week phase 3 REDEFINE 1 trial, once-weekly subcutaneous semaglutide 2.4 mg plus cagrilintide 2.4 mg in adults without diabetes with obesity, or overweight with at least one related complication, gastrointestinal adverse events affected 79.6% of the combination group versus 39.9% on placebo: nausea, vomiting, diarrhea, constipation or abdominal pain. The events were mainly transient and mild-to-moderate in severity. [1]

These are data for the pharmaceutical combination at the studied doses, rather than one reaction frequency. The abstract does not establish the safety of the catalog reagent. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Gastrointestinal adverse events overallAdults without diabetes with obesity, or overweight with at least one related complication; semaglutide 2.4 mg plus cagrilintide 2.4 mg subcutaneously once weekly, 68 weeks (REDEFINE 1)79.6% in the combination group versus 39.9% on placebo (very common on the pharmacy scale, ≥10%); mainly transient and mild-to-moderate in severity[1]
NauseaThe same participantsNamed among the gastrointestinal events; no separate frequency in the abstract[1]
VomitingThe same participantsNamed among the gastrointestinal events; no separate frequency given[1]
DiarrheaThe same participantsNamed among the gastrointestinal events; no separate frequency given[1]
ConstipationThe same participantsNamed among the gastrointestinal events; no separate frequency given[1]
Abdominal painThe same participantsNamed among the gastrointestinal events; no separate frequency given[1]

References

  1. W Timothy Garvey et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity https://doi.org/10.1056/NEJMoa2502081.